Citations

Clear

9383 citation(s) found for "Thomas, PS".

Nucleus Freedom North American Clinical Trial
Bałkany, Thomas J., Hodges, Annelle V., Menapace, Christine, Hazard, Linda, Driscoll, Colin L. W., Gantz, Bruce J. , Kelsall, David C., Luxford, William M., McMenomy, Sean, Neely, J. Gail, Peters, B. Robert, Pillsbury, Harold C., Roberson, Joseph, Schramm, David , Telian, Steven A., Westerberg, Brian D. , Payne, Stacy L., Waltzman, Susan B.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | May 1, 2007 | Volume: 136 | Issue: 5 | Pages: 757-762

10.1016/j.otohns.2007.01.006 | PMID 17478211 Get It

OBJECTIVETo evaluate hearing outcomes and effects of stimulation rate on performance with the Nucleus Freedom cochlear implant (Cochlear Americas, Denver, CO).STUDY DESIGN AND SETTINGRandomized, controlled, prospective, single‐blind clinical study using single‐subject repeated measures (A‐B‐A‐B) design at 14 academic centers in the United States and Canada and comparison with outcomes of a prior device by the same manufacturer.PATIENTSSeventy‐one severely/profoundly hearing impaired adults.RESULTSSeventy‐one adult recipients were randomly programmed in two different sets of rate: ACE or higher rate ACE RE. Mean scores for Consonant Nucleus Consonant words is 57%, Hearing in Noise Test (HINT) sentences in quiet 78%, and HINT sentences in noise 64%. Sixty‐seven percent of subjects preferred slower rates of stimulation, and performance did not improve with higher rates of stimulation using this device.CONCLUSIONSSubjects performed well, and there was no advantage to higher stimulation rates with this device.SIGNIFICANCEHigher stimulation rates do not necessarily result in improved performance.
IDOCS: Intelligent Distributed Ontology Consensus System—The Use of Machine Learning in Retinal Drusen Phenotyping
Thomas, George, Grassi, Michael A. , Lee, John R. , Edwards, Albert O., Casavant, Thomas L. , Scheetz, Todd E. , Stone, Edwin M. , Williams, Andrew B. , Gorin, Michael B. , Klein, Ronald

Mayo Clinic

Investigative Opthalmology & Visual Science | April 25, 2007 | Volume: 48 | Issue: 5 | Pages: 2278

10.1167/iovs.06-1022 | PMID 17460291 Get It

Percutaneous Cryoablation of Large Renal Masses: Technical Feasibility and Short-Term Outcome
Atwell, Thomas D. , Farrell, Michael A., Callstrom, Matthew R. , Charboneau, J. William, Leibovich, Bradley C. , Frank, Igor, Patterson, David E.

Mayo Clinic

American Journal of Roentgenology | April 20, 2007 | Volume: 188 | Issue: 5 | Pages: 1195-1200

10.2214/ajr.06.1152 | PMID 17449758 Get It

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, Bruce J. , Catalano, Paul J. , Meropol, Neal J. , O’Dwyer, Peter J. , Mitchell, Edith P. , Schwartz, Michael , Benson, Al B. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | April 18, 2007 | Volume: 25 | Issue: 12 | Pages: 1539-1544

10.1200/jco.2006.09.6305 | PMID 17442997 Get It

Purpose Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. Patients and Methods Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity. Results The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively (P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. Conclusion The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.
Proteomic Analysis of Waldenstrom Macroglobulinemia
Hatjiharissi, Evdoxia , Ngo, Hai T., Leontovich, Alexey A. , Leleu, Xavier , Timm, Michael, Melhem, Mona F., George, Diane, Lu, Ganwei, Alsayed, Yazan, Zeismer, Steven C., Cabanela, Miguel E., Nehme, Alex, Jia, Xiaoying , Moreau, Anne Sophie, Fonseca, Rafaël , Ghobrial, Joanna M. , Moreau, Anne Sophie, Treon, Steven P. , Gertz, Morie A. , Anderson, Kenneth C. , Witzig, Thomas E. , Ghobrial, Irene M. , Fonseca, Rafael

Mayo Clinic

Cancer Research | April 17, 2007 | Volume: 67 | Issue: 8 | Pages: 3777-3784

10.1158/0008-5472.can-06-3089 | PMID 17440091 Get It

Abstract To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a &gt;2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by &gt;2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKα. Other proteins up-regulated by &gt;1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by &gt;2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics. [Cancer Res 2007;67(8):3777–8]
Higher Frequency of Diploidy in Young-Onset Microsatellite-Stable Colorectal Cancer
Boardman, Lisa A., Johnson, Ruth, Petersen, Gloria M. , Oberg, Ann L. , Kabat, Brian, Slusser, Joshua P. , Morlan, Bruce W., French, Amy J. , Smyrk, Thomas C. , Lindor, Noralane M. , Thibodeau, Stephen N. , Boardman, Lisa A., Wang, Liang

Mayo Clinic

Clinical Cancer Research | April 16, 2007 | Volume: 13 | Issue: 8 | Pages: 2323-2328

10.1158/1078-0432.ccr-06-2739 | PMID 17438090 Get It

AbstractPurpose: Colorectal carcinoma (CRC) can be divided into two nonoverlapping groups: those that are chromosomally unstable but microsatellite stable (MSS CIN+) and those that are chromosomally stable but microsatellite unstable (MSI CIN−). However, a third group with neither chromosome nor microsatellite instability (MSS CIN−) makes a substantial contribution to the total CRC burden. The clinicopathologic features of MSS CIN− CRC are not well delineated. We assessed the relationship between age and chromosomal instability (CIN) status as measured by ploidy and allelic imbalance in a series of MSS tumors.Experimental Design: We studied a prospectively collected series of CRC patients at Mayo Clinic Rochester. A total of 84 samples of MSS CRC in patients ≤50 years old were identified between 1994 and 1997. A consecutive series of 90 MSS CRC in patients ≥65 years old served as a comparison group. CIN status was assessed using two techniques: ploidy analysis by flow cytometry and small chromosome changes as measured by genomewide fractional allelic imbalance.Results: CRC in the young-onset group was more likely to involve the rectum and to be high stage. MSS tumors in the young-onset group were more often diploid (46%) than those in older patients (26%; P = 0.006). This difference was maintained in the subset of MSS CRC that were high stage (42% versus 18%; P = 0.02) and in rectal cancers (50% versus 23%; P = 0.04).Conclusion: A greater proportion of young patients with MSS CRC has diploid tumors than patients who develop MSS CRC over age 65.
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Heemers, Hannelore V. , Sebo, Thomas J., Debes, José D. , Regan, Kevin M., Raclaw, Kristin A., Murphy, Linda M., Hobisch, Alfred, Tindall, Donald J., Čulig, Zoran

Mayo Clinic

Cancer Research | April 5, 2007 | Volume: 67 | Issue: 7 | Pages: 3422-3430

10.1158/0008-5472.can-06-2836 | PMID 17409453 Get It

Abstract Standard therapy for nonorgan confined prostate cancer aims to block the production or action of androgens. Although initially successful, antiandrogen therapy eventually fails and androgen depletion independent (ADI) disease emerges. Remarkably, ADI prostate cancers still rely on a functional androgen receptor (AR). Aberrant expression of coregulatory proteins required for the formation of productive AR transcriptional complexes is critical for ADI AR activation. Previously, we have shown that the transcriptional coactivator p300 is required for ADI activation of the AR and is up-regulated in prostate cancer, in which its expression is associated with cell proliferation and predicts aggressive tumor features. The mechanism responsible for the deregulated expression of p300, however, remains elusive. Here, we show that p300 expression in prostate cancer cells is subject to androgen regulation. In several prostate cancer model systems, addition of synthetic and natural androgens led to decreased expression of p300 in a time-dependent and dose-dependent manner. Experiments using AR antagonists or small interfering RNA targeting the AR revealed that down-regulation of p300 depends entirely on the presence of a functional AR. It is noteworthy that androgens down-regulated p300 protein expression while leaving messenger levels unaltered. Conversely, both short-term and long-term androgen deprivation resulted in marked up-regulation of p300 expression. The androgen deprivation–induced increase in p300 expression was not affected by the addition of cytokines or growth factors or by cotreatment with antiandrogens. Moreover, increased p300 expression upon androgen starvation is crucial for prostate cancer cell proliferation, as loss of p300 expression severely reduces expression of cyclins governing G1-S and G2-M cell cycle transition and decreases 5-bromo-2′-deoxyuridine incorporation. [Cancer Res 2007;67(7):3422–30]
Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer
Gayther, Simon A. , Song, Honglin , Ramus, Susan J. , Kjær, Susanne K. , Whittemore, Alice S. , Quaye, Lydia, Shadforth, Danielle, Høgdall, Estrid , Høgdall, Claus , Blaeker, Jan, DiCioccio, Richard A., McGuire, Valerie , Webb, Penelope M. , Beesley, Jonathan, Whiteman, David C. , Group, The Australian Ovarian Cancer Study, Cancer), The Australian Cancer Study (Ovarian, Goodman, Marc T. , Lurie, Galina, Carney, Michael E., Ness, Roberta B., Edwards, Robert P., Moysich, Kirsten B., Goode, Ellen L. , Cunningham, Julie M. , Sellers, Thomas A. , Wu, Anna H. , Pike, Malcolm C. , Iversen, Edwin S., Marks, Jeffrey R. , García‐Closas, Montserrat , Brinton, Louise A. , Lissowska, Jolanta , Pepłońska, Beata , Easton, Douglas F. , Jacobs, Ian , Ponder, Bruce A.J., Schildkraut, Joellen M. , Pearce, Celeste Leigh, Chenevix‐Trench, Georgia , Pharoah, Paul D.P., Blaakær, Jan , Tyrer, Jonathan P. , Green, Adèle C. , Group, The Australian Ovarian Cancer Study, Cancer), The Australian Cancer Study (Ovarian, Modugno, Francesmary , Couch, Fergus J. , Berchuck, Andrew , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Whiteman, David C , Goodman, Marc T

Mayo Clinic

Cancer Research | April 4, 2007 | Volume: 67 | Issue: 7 | Pages: 3027-3035

10.1158/0008-5472.can-06-3261 | PMID 17409409 Get It

Abstract High-risk susceptibility genes explain &lt;40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)–tagging approach to evaluate common variants in 13 genes involved in cell cycle control—CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D—and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark (∼1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States (∼2,000 cases and ∼3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85–0.98) for rs3731257; and OR, 0.93 (0.87–0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies. [Cancer Res 2007;67(7):3027–35]
Association of Ambulatory Blood Pressure With Ischemic Brain Injury
Schwartz, Gary L. , Bailey, Kent R. , Jack, Clifford R. , Canzanello, Vincent J., Mosley, Thomas H. , Knopman, David S. , Turner, Stephen T. , Jack, Clifford R

Mayo Clinic

Hypertension | April 3, 2007 | Volume: 49 | Issue: 6 | Pages: 1228-1234

10.1161/hypertensionaha.106.078691 | PMID 17404188 Get It

Cerebral white matter hyperintensities on brain MRI (leukoaraiosis) are associated with increased risk of stroke and dementia. To assess the relationships of blood pressure level and circadian pattern with leukoaraiosis, we obtained 24-hour ambulatory blood pressure recordings and brain magnetic resonance images in 343 white and 267 black adults who were members of sibships that had ≥2 siblings with essential hypertension. In multiple linear regression models, factors associated with greater leukoaraiosis in both racial groups included age ( P ≤0.002), homocysteine levels ( P ≤0.006), and brain volume ( P ≤0.008). In blacks, ambulatory blood pressure measures associated with greater leukoaraiosis were higher awake, asleep, and 24-hour systolic and diastolic levels ( P ≤0.009 for each). In addition, there was a trend for smaller nocturnal declines in systolic and diastolic levels (ie, nondipping patterns) to be associated with greater leukoaraiosis, and all of these associations, except nondipping of diastolic level, remained or became significant after controlling for office blood pressure ( P <0.05 for each). In whites, among ambulatory blood pressure measures, only higher asleep diastolic levels trended toward association with greater leukoaraiosis. However, similar to findings in blacks, nondipping of systolic and diastolic ambulatory blood pressure levels were each associated with greater leukoaraiosis ( P ≤0.008), and all of these associations remained or became significant after controlling for office blood pressure ( P ≤0.009 for each). Higher ambulatory blood pressure levels and a nondipping circadian pattern contribute to greater leukoaraiosis volume after controlling for office blood pressure.
Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Siddiqui, Sameer , Frigola, Xavier, Bonne-Année, Sandra, Mercader, Maria, Kuntz, Susan M., Krambeck, Amy E. , Sengupta, Shomik , Cheville, John C. , Lohse, Christine M. , Krco, Christopher J., Webster, W. Scott, Leibovich, Bradley C. , Blute, Michael L., Knutson, Keith L. , Kwon, Eugene D., Dong, Haidong , Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | April 2, 2007 | Volume: 13 | Issue: 7 | Pages: 2075-2081

10.1158/1078-0432.ccr-06-2139 | PMID 17404089 Get It

AbstractPurpose: Regulatory T cells (Tregs) have been implicated as inhibitors of antitumoral immunity, and evidence suggests that elimination of Tregs may augment natural and pharmacologic immunity. We tested for the presence of putative Tregs within renal cell carcinoma (RCC) tumors.Experimental Design: We identified 170 patients who underwent radical or partial nephrectomy for clear cell RCC between 2000 and 2002. Specimens were stained with anti-CD4, anti-CD25, and anti-Foxp3 antibodies and examined using confocal microscopy. Associations of CD4+CD25+Foxp3− and CD4+CD25+Foxp3+ T cells with death from RCC were evaluated using Cox proportional hazards regression models.Results: At last follow-up, 46 of 170 patients had died; of these, 37 died from RCC at a median of 1.4 years following nephrectomy (range, 0-4.4). Among the 124 remaining patients, median follow-up was 3.7 years (range, 0-5.7). Forty-three (25.3%) tumors harbored CD4+CD25+Foxp3+ T cells. The presence of Foxp3+ T cells was not significantly associated with RCC death univariately. One hundred forty-three (84.1%) tumors harbored CD4+CD25+Foxp3− T cells. The indicator for ≥10% CD4+CD25+Foxp3− T cells was significantly associated with RCC death univariately [risk ratio (RR), 2.60; 95% confidence interval (95% CI), 1.35-4.98; P = 0.004], after adjusting for tumor B7-H1 expression (RR, 2.53; 95% CI, 1.32-4.85; P = 0.005) and lymphocytic infiltration (RR, 2.53; 95% CI, 1.32-4.87; P = 0.005).Conclusions: Increased presence of CD4+CD25+Foxp3+ T cells was not significantly associated with RCC death. In contrast, CD4+CD25+Foxp3− T cells, which may represent a unique set of Tregs or activated helper T cells, was significantly associated with outcome.